Un-audited Financial Results for the three and six months period ended 30 ${ }^{\text {th }}$ September, 2011
Rs. lakhs

|  | THREE <br> MONTHS ENDED <br> $30^{\text {TH }}$ <br> SEPTEMBER, <br> 2011 <br> (REVIEWED) | CORRESPONDING THREE MONTHS IN THE PREVIOUS YEAR <br> (UN-AUDITED) | YEAR TO DATE FIGURES FOR THE CURRENT YEAR (REVIEWED) | YEAR TO DATE FIGURES FOR THE PREVIOUS YEAR (UN-AUDITED) | PREVIOUS ACCOUNTING YEAR 31-03-2011 (AUDITED) |
| :---: | :---: | :---: | :---: | :---: | :---: |
| 01. Net Sales / Income from Operations (including Excise Duty \& Sales Tax) | 10479 | 8695 | 19963 | 17114 | 33826 |
| 02. Other Operating I ncome | 814 | 732 | 1516 | 1322 | 3348 |
| 03. TOTAL I NCOME | 11293 | 9427 | 21479 | 18436 | 37174 |
| 04. EXPENDITURE |  |  |  |  |  |
| a) Increase / Decrease in Stock-in-Trade and work-in-progress | -67 | -265 | -135 | -496 | -1148 |
| b) Consumption of Raw Materials | 2662 | 2511 | 5670 | 5124 | 9742 |
| c) Purchase of traded goods | 588 | 272 | 929 | 629 | 1672 |
| d) Employees Cost | 1510 | 1338 | 2966 | 2612 | 5112 |
| e) Depreciation | 378 | 377 | 756 | 705 | 1435 |
| f) Other Expenditure | 3597 | 2899 | 6521 | 5868 | 12616 |
| g) TOTAL | 8668 | 7132 | 16707 | 14442 | 29429 |
| 05. Profit from Operations before other income, interest | 2625 | 2295 | 4772 | 3994 | 7745 |
| 06. Other I ncome | 156 | 28 | 261 | 61 | 72 |
| 07. Interest | 595 | 420 | 1125 | 762 | 1419 |
| 08. Profit / (Loss) from ordinary activities before tax | 2186 | 1903 | 3908 | 3293 | 6398 |
| 09. Tax expense, including deferred tax | 583 | 431 | 928 | 777 | 1186 |
| 10. Net Profit / Loss (-) from ordinary activities after tax | 1603 | 1472 | 2980 | 2516 | 5212 |
| 11. Paid-up Equity Share Capital (each share of Rs. 10/- face value) | 2815 | 2815 | 2815 | 2815 | 2815 |
| 12. Reserves excluding revaluation reserves as per Balance Sheet of previous accounting year | - | - | - | - | 31876 |
| 13. Earnings per share - Basic and diluted EPS before and after extraordinary item (Rs.) | 5.69/5.69 | 5.23/5.23 | 10.59/10.59 | 8.94/8.94 | 18.52/18.52 |
| 14. Public Shareholding: <br> a) Number of Shares <br> b) Percentage of Shareholding | $\begin{array}{r} 10,383,626 \\ 36.89 \end{array}$ | $\begin{array}{r} 10,522,255 \\ 37.38 \end{array}$ | $\begin{array}{r} 10,383,626 \\ 36.89 \end{array}$ | $\begin{array}{r} 10,522,255 \\ 37.38 \end{array}$ | $\begin{array}{r} 10,459,455 \\ 37.16 \end{array}$ |
| 15. Promoters and Promoter Group Shareholding <br> a) Pledged / Encumbered - No. of shares <br> Percentage (as a \% of the total shareholding of promoter and promoter group) <br> Percentage (as a \% of the total share capital of the company) <br> b) Non - encumbered - No. of shares Percentage (as a \% of the total shareholding of promoter and promoter group) <br> Percentage (as a \% of the total share capital of the company) | $\begin{array}{r} 1,050,000 \\ 5.91 \\ 3.73 \\ \\ 16,714,326 \\ 94.09 \\ 59.38 \end{array}$ | $1,050,000$ 5.96 3.73 $16,575,697$ 94.04 58.89 | $1,050,000$ 5.91 3.73 $16,714,326$ 94.09 59.38 | $1,050,000$ 5.96 3.73 $16,575,697$ 94.04 58.89 | $\begin{array}{r} 1,050,000 \\ 5.94 \\ 3.73 \\ \\ 16,638,497 \\ 94.06 \\ 59.11 \end{array}$ |

The above un-audited financial results were reviewed by the Audit Committee and approved by the Board of Directors at a meeting held at Hyderabad, on Wednesday, the $9^{\text {th }}$ November, 2011. The net sales /income from operations include sales tax of (Rs. lakhs) 305, 508, 220, 428 and 854 and excise duty of (Rs. lakhs) $61,118,56,107$ and 264 respectively for the quarter and half year ended on $30^{\text {th }}$ September, 2011, $30^{\text {th }}$ September, 2010 and for the year ended on $31^{\text {st }}$ March, 2011. There are no exceptional and extraordinary items to be reported for the period under review. In respect of matters referred to in the limited review report by the Auditors relating to non-accounting of minimum alternative tax credit amounting to (Rs. lakhs) 514, 710, 295, 637 and 2921 for the three and six months ended $30^{\text {th }}$ September, 2011 and 2010 and for the year ended $31^{\text {st }}$ March, 2011 respectively, the company will review the position at the end of the financial year ending 31 March 2012. Figures for the previous period(s) have been re-arranged / re-grouped wherever necessary.

Dated at Hyderabad, this, the $9^{\text {th }}$ day of November, 2011.
for and on behalf of the Board of Directors,
NATCO Pharma Limited

| Status of Investor Complaints as at 30 |  |
| :--- | ---: |
| Pen September, 2011 |  |
|  |  |
| Pending as on 01-07-2011 | Nil |
| Received during the quarter | 35 |
| Resolved during the quarter | 35 |
| Pending as on 30-09-2011 | Nil |

- +inconn
V.C. Nannapaneni

Chairman \& Managing Director

Un-audited Financial Results (consolidated) for the three and six months period ended 30th September, 2011


The above un-audited financial results were reviewed by the Audit Committee and approved by the Board of Directors at a meeting held at Hyderabad, on Wednesday, the $9^{\text {th }}$ November, 2011. The net sales lincome from operations include sales tax of (Rs. lakhs) 305, 508, 220, 428 and 854 and excise duty of (Rs. lakhs) $61,118,56,107$ and 264 respectively for the quarter and half year ended on $30^{\text {th }}$ September, 2011, $30^{\text {th }}$ September, 2010 and for the year ended on $31^{\text {st }}$ March, 2011. There are no exceptional and extraordinary items to be reported for the period under review.. Figures for the previous period(s) have been rearranged / re-grouped wherever necessary.The stand-alone results are available on the company's website www.natcopharma.co.in as well as at the Registered Office of the Company.

Dated at Hyderabad, this, the 9th November, 2011.
for and on behalf of the Board of Directors,
Status of Investor Complaints as at $30^{\text {th }}$ September,

NATCO Pharma Limited
V.C. Nannapaneni

Chairman \& Managing Director

## Statement of Assets \& Liabilities

Rs. In lakhs

| Particulars | As at 30-09-2010 (un-audited) | As at 30-09-2011 (un-audited) |
| :---: | :---: | :---: |
| Shareholders' Funds |  |  |
| (a) Capital | 2815 | 2815 |
| (b) Reserves \& Surplus | 29854 | 34956 |
| Loan Funds | 15552 | 27081 |
| Deferred Tax Liability | 2802 | 2650 |
| TOTAL | 51023 | 67502 |
|  |  |  |
| Fixed Assets | 29371 | 43555 |
| Investments | 9603 | 7345 |
| Current Assets, Loans and Advances |  |  |
| (a) Inventories | 7390 | 9358 |
| (b) Sundry Debtors | 6160 | 8253 |
| (c) Cash \& Bank Balances | 1238 | 3058 |
| (d) Loans and Advances | 5286 | 10959 |
| Less : Currnt Liabilities and Provisions | 8025 | 15026 |
| $\underline{\underline{\text { TOTAL }}}$ | 51023 | 67502 |

## Report of segment wise Revenue, Results and Capital Employed,(un-audited) under Clause 41 of the Listing Agreement, for the quarter ended on $30^{\text {th }}$ September, 2011

Rs. lakhs

| Particulars | Three months ended on $30^{\text {ot }}$ September, 2011 | Corresponding three months in the previous year | Year to date figures for the current year | Year to date figures for the previous year | Previous Accounting Year (2010-2011) |
| :---: | :---: | :---: | :---: | :---: | :---: |
| 1. Segment Revenue (net sales / income, including Sales Tax) |  |  |  |  |  |
| a) Bulk Chemicals | 4114 | 2843 | 8808 | 5756 | 12012 |
| b) Formulations | 6828 | 6316 | 12670 | 12185 | 23211 |
| c) J ob Work | 233 | 246 | 463 | 449 | 1098 |
| d) Unallocated (Others) | 678 | 515 | 494 | 871 | 2203 |
| Total | 11853 | 9920 | 22435 | 19261 | 38524 |
| Less : Inter-segment Revenue | 403 | 465 | 692 | 764 | 1350 |
| Net Sales / Income from Operations | 11450 | 9455 | 21743 | 18497 | 37174 |
| 2. Segment Results : Profit (+) / Loss (-) before tax and interest |  |  |  |  |  |
| a) Bulk Chemicals | 937 | 270 | 1720 | 544 | 1458 |
| b) Formulations | 2799 | 2680 | 5011 | 4904 | 11001 |
| c) J ob Work | 179 | 211 | 368 | 376 | 872 |
| d) Unallocated (Others) | -1133 | -838 | -2065 | -1769 | -5513 |
| Total | 2782 | 2323 | 5034 | 4055 | 7818 |
| Less : a) Interest | 596 | 420 | 1126 | 762 | 1420 |
| Total Profit before Tax | 2186 | 1903 | 3908 | 3293 | 6398 |
| 3. Capital Employed (Segment Assets - Segment Liabilities) |  |  |  |  |  |
| a) Bulk Chemicals | 23233 | 7561 | 23233 | 7561 | 15055 |
| b) Formulations | 23914 | 10125 | 23914 | 10125 | 23390 |
| c) Job Work | 150 | - | 150 | - | 216 |
| d) Unallocated (Others) | -9527 | 14883 | -9527 | 14883 | -3971 |
| Total | 37770 | 32569 | 37770 | 32569 | 34690 |

The above report of segment-wise revenue, results and capital employed for the three months ended on $30^{\text {th }}$ September, 2011 was considered and taken on record by the Board of Directors at a meeting held at Hyderabad, on Wednesday, the $9^{\text {th }}$ November, 2011.

Dated at Hyderabad, this, the $9^{\text {th }}$ November, 2011.
for and on behalf of the Board of Directors,
NATCO Pharma Limited,
打列
V.C. Nannapaneni

Chairman \& Managing Director

